公开(公告)号：US20140336166A1

公开(公告)日：2014-11-13

申请号：US14353950

申请日：2012-10-26

Applicant: NOVARTIS AG

Inventor： Emmanuelle Briard ,  Pascal Furet ,  Andreas Lerchner ,  Peter Meier ,  Branko Radetich ,  David Andrew Sandham ,  Yanyi Zhu

IPC: C07D473/16 ,  C07D491/048 ,  C07D491/107 ,  A61K31/5377 ,  A61K31/553

CPC classification number: C07D473/16 ,  A61K31/5377 ,  A61K31/553 ,  C07D487/04 ,  C07D491/048 ,  C07D491/107 ,  C07D519/00

Abstract: The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.

Abstract translation: 本发明涉及式（I）的PI3K抑制剂，其中所有变量如说明书中所定义，其制备，其医疗用途，特别是其在治疗癌症和神经变性疾病中的用途，以及 包括它们的药物。

公开(公告)号：US10202371B2

公开(公告)日：2019-02-12

申请号：US15047574

申请日：2016-02-18

Applicant: Novartis AG

Inventor： Robin Alec Fairhurst ,  Pascal Furet ,  Frank Stephen Kalthoff ,  Andreas Lerchner ,  Heinrich Rueeger

IPC: A61K31/5377 ,  A61K45/06 ,  C07D417/14 ,  C07D413/14

Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

公开(公告)号：US20190382399A1

公开(公告)日：2019-12-19

申请号：US16224212

申请日：2018-12-18

Applicant: Novartis AG

Inventor： Robin Alec Fairhurst ,  Pascal Furet ,  Frank Stephen Kalthoff ,  Andreas Lerchner ,  Heinrich Rueeger

IPC: C07D417/14 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/14

Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.